Determinants of Medication Non-Adherence Among Patients With Chronic Diseases in Egyptian Communi… (NCT07375550) | Clinical Trial Compass
CompletedNot Applicable
Determinants of Medication Non-Adherence Among Patients With Chronic Diseases in Egyptian Community Pharmacies
Egypt261 participantsStarted 2026-01-01
Plain-language summary
Medication non-adherence among patients with chronic diseases is a major public health concern and is associated with poor disease control, increased complications, and higher healthcare costs. Community pharmacists play an important role in supporting patients' medication use through counseling and education; however, the determinants of medication non-adherence among patients attending community pharmacies in Egypt are not well characterized.
This multicenter, cross-sectional study aims to assess the prevalence of medication non-adherence and identify factors associated with non-adherence among adult Egyptian patients with chronic diseases attending community pharmacy settings. Medication adherence will be evaluated using the Adherence in Chronic Diseases Scale (ACDS), along with sociodemographic, clinical, and medication-related factors. The findings are expected to provide evidence to inform strategies for improving medication adherence and optimizing chronic disease management in community pharmacy practice in Egypt.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 18 to 80 years.
* Diagnosed with at least one chronic disease requiring long-term pharmacological treatment.
* Currently receiving at least one prescribed medication for a chronic condition.
* Attending a participating community pharmacy during the study period.
* Able and willing to provide written informed consent.
Exclusion Criteria:
* Patients with cognitive impairment or mental conditions that limit their ability to understand the study procedures or complete the questionnaire.
* Patients who refuse or are unable to provide written informed consent.
* Patients who are acutely ill and unable to participate at the time of data collection.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Prevalence of Medication Non-Adherence Among Patients with Chronic Diseases
Timeframe: Through study completion, an average of 1 month (cross-sectional assessment)